IntroductionA significant number of patients with COVID-19 may experience dyspnoea, anxiety, depression, pain, fatigue and physical impairment symptoms, raising the need for a multidisciplinary rehabilitation approach, especially for those with advanced age, obesity, comorbidities and organ failure. Traditional pulmonary rehabilitation (PR), including exercise training, psychosocial counselling and education, has been employed to improve pulmonary function, exercise capacity and quality of life in patients with COVID-19. However, the effects of inspiratory muscle training (IMT) in PR programmes remain unclear. This study aimed to determine whether the addition of a supervised IMT in a PR is more effective than PR itself in improving dyspnoea, health-related quality of life and exercise capacity in symptomatic patients with post-COVID-19.Methods and analysisThis parallel-group, assessor-blinded randomised controlled trial, powered for superiority, aimed to assess exercise capacity as the primary outcome. A total of 138 are being recruited at two PR centres in Brazil. Following baseline testing, participants will be randomised using concealed allocation, to receive either (1) standard PR with sham IMT or (2) standard PR added to IMT. Treatment effects or differences between the outcomes (at baseline, after 8 and 16 weeks, and after 6 months) of the study groups will be analysed using an ordinary two-way analysis of variance.Ethics and disseminationThis trial was approved by the Brazilian National Ethics Committee and obtained approval on 7 October 2020 (document number 4324069). The findings will be disseminated through publications in peer-reviewed journals and conference presentations.Trial registration numberNCT04595097.

Background: In response to the pandemic caused by COVID-19, World Health Organization (WHO), together with International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), developed research protocols facilitating global collaboration and accelerating the understanding of the disease, to identify the potential symptoms and persistent sequelae in infected individuals, which can be used in different areas of health, that is, in primary care, at a hospital or outpatient level, both public and private. Objective: To describe the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) protocol as a new global collaborative platform for global clinical trials targeting post-COVID-19 patients. Methods: The standardized forms were developed from the COVID-19 Clinical Characterization Protocol (PCC) by the ISARIC/WHO working group composed of specialist researchers with experience in clinical research in different areas of medicine and public health, especially outbreaks and infectious diseases. Conclusion: It is expected that the creation of a database composed of different populations from all over the world will help in the characterization of risk factors, in the best form of clinical intervention and in the best prevention strategies for physical, neurological and psychosocial sequelae in the medium and long term in post-COVID-19 patients.

Background: Global estimates point to high prevalence of neuropsychiatric disorders in individuals hospitalized for COVID-19. In Brazil, anxiety and depression rates resulting from SARS-CoV-2 infection range from 29.7% to 68%, respectively, being more prevalent in young women, with lower educational level, with comorbidities and psychological problems. previous. Objective: Identify possible causes, verify prevalence and identify risk factors for anxiety, depression and post-traumatic stress disorder (PTSD) in patients hospitalized for COVID-19. Methods: An integrative literature review was carried out involving retrospective and/or prospective cohort studies and population-based clinical trials published in the last three years. The main evidence on the relationship between neuropsychiatric disorders and intrinsic changes in neuroimmunomodulation parameters was also raised. Results: Twenty-one studies were included that addressed the presence of symptoms of PTSD, anxiety, depression, fatigue in sleep disorders in COVID19 survivors. Conclusion: With this literature review, it can be concluded that PTSD, anxiety, depression, fatigue and sleep disturbances are highly prevalent symptoms in COVID-19 survivors, being persistent for up to one-year post-infection.